Skip to main content

Arcturus Therapeutics Holdings Inc.

corporate_fare Company Profile

Arcturus Therapeutics Holdings Inc.

ARCT·NASDAQ·Life Sciences·CIK 0001768224

We are a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases. We are conducting Phase 2 clinical studies for RNA therapeutic candidates targeting ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). We developed KOSTAIVE®, the world's first approved self-amplifying messenger RNA (sa-mRNA) vaccine, in partnership with Seqirus, Inc. (CSL Seqirus), a part of CSL Limited. KOSTAIVE® is approved in Japan, the European Union, and the United Kingdom as a COVID-19 vaccine, with sales commencing in Japan in October 2024. We utilize key platform technologies to advance a pipeline of mRNA-based therapeutics for rare genetic disorders and vaccines for infectious diseases. Our mRNA medicines consist of messenger RNA (mRNA) constructs and lipid nanoparticles (LNP) for delivery. We specialize in designing and optimizing mRNA constructs, including self-amplifying mRNA (sa-mRNA). Our proprietary self-amplifying mRNA technology platform, STARR®, has shown to induce a robust, longer-lasting, and broader humoral immune response at lower doses compared to conventional mRNA-based vaccines. Our proprietary LNP delivery system, LUNAR®, aims to effectively and safely deliver RNA to target tissues, potentially enabling multiple nucleic acid medicines. We also possess expertise in developing and scaling manufacturing processes for nucleic acid medicines. Our internal pipeline includes RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). In our vaccine program, we partner with CSL Seqirus on the development and commercialization of mRNA vaccines for COVID-19, influenza, and three other infectious diseases.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for ARCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARCT spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Meiji Buys $50M of Arcturus Stock at 80% Premium, Expands mRNA Collaboration
  • Arcturus Q3 10-Q: Loss Narrows to $7.4M, $184.8M Cash, CSL Exit Booked
  • Q3 Net Loss Halves to $7.4M as Arcturus Guides Cash Runway to 2028
  • FDA Endorses Ammonia as Key Pediatric Endpoint; Arcturus Adds ARCT-2601 to Phase 2 Trial
  • Arcturus Buys AI Drug Discovery Firm myNEO, Reports Positive OTCD Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$82.03M
Net Income
-$65.78M
Diluted EPS
-$2.40
Op. Cash Flow
-$74.27M
Free Cash Flow
-$74.5M
Operating Income
-$76.26M
Cash & Equivalents
$230.91M
Debt / Equity
0.00×
Net Margin
-80.2%
Shares Outstanding
28.41M sh
Source: 10-K · filed 2026-03-03 · accession 0001193125-26-088391

Short Interest & Short Volume

7.37 days to cover

FINRA reported short interest of 5,409,475 shares in ARCT as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 7.4 days to cover at its recent average daily volume. On November 20, 2026, 55.3% of ARCT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,409,475 shares as of October 30, 2026
Change vs prior period▼ 0.9%
Days to cover7.37 at avg daily volume of 734,287
Daily short volume (FINRA facilities)55.3% of 169,779 shares on November 20, 2026
5-day average short volume59.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$7.55 +1.34% today
52-week range · as of 2026-11-16 $5.5 – $17.96
Market cap
$214.73M
Volume
602K (0.9× avg)
3-mo avg 649.8K
Live data · 2026-11-22 08:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARCT - Latest Insights

ARCT
Nov 16, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.52
Real-time Price: $7.55 info
Change: -$0.970 (-11%) info
Market Cap: $214.728M info
ARCT
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.90
Real-time Price: $7.55 info
Change: -$2.35 (-24%) info
Market Cap: $214.728M info
ARCT
Nov 05, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.34
Real-time Price: $7.55 info
Change: -$1.79 (-19%) info
Market Cap: $214.728M info
ARCT
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $7.55 info
Change: -$6.25 (-45%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info
ARCT
Aug 06, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $6.08
Real-time Price: $7.55 info
Change: +$1.47 (+24%) info
Market Cap: $214.728M info
ARCT
Jul 02, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $7.25
Real-time Price: $7.55 info
Change: +$0.300 (+4%) info
Market Cap: $214.728M info
ARCT
Jul 02, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.15
Real-time Price: $7.55 info
Change: +$0.4012 (+6%) info
Market Cap: $214.728M info
ARCT
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $7.17
Real-time Price: $7.55 info
Change: +$0.380 (+5%) info
Market Cap: $214.728M info
ARCT
May 07, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.43
Real-time Price: $7.55 info
Change: +$0.120 (+2%) info
Market Cap: $214.728M info
ARCT
May 07, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.50
Real-time Price: $7.55 info
Change: +$0.050 (+0.67%) info
Market Cap: $214.728M info
ARCT
Mar 03, 2026, 4:34 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $7.48
Real-time Price: $7.55 info
Change: +$0.0696 (+0.93%) info
Market Cap: $214.728M info
ARCT
Mar 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.83
Real-time Price: $7.55 info
Change: -$0.280 (-4%) info
Market Cap: $214.728M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets